Drugs / TDM-621
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03917862 | Dec 2018 → Dec 2020 | aneurysm or dilatation of ascending aorta, arterial disorder | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-09-25 | Kaken Pharmaceutical | 吸収性局所止血材「TDM-621」の販売提携に関する準独占的販売権許諾契約締結のお知らせ eir-parts.net ↗ |
| 2012-04-09 | Kaken Pharmaceutical | 吸収性局所止血材「TDM-621」の販売提携に関する基本合意書締結のお知らせ eir-parts.net ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDM-621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03917862 ↗ |
| Modality | Peptide | “composed of nanofibers of a self-supporting polypeptide” NCT03917862 ↗ |